Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing
Podcast Image

Optimum Perspectives

Business Science Health & Fitness

Activity Overview

Episode publication activity over the past year

Episodes

How sleep architecture shapes brain health: new frontiers in Alzheimer’s research

13 Mar 2026

Contributed by Lukas

On World Sleep Day 2026, Optimum is marking the occasion with a brand-new podcast episode featuring Magnus Ivarsson, CSO of AstronauTx and Prof. Liz C...

How sleep architecture shapes brain health: new frontiers in Alzheimer’s research

13 Mar 2026

Contributed by Lukas

On World Sleep Day 2026, Optimum is marking the occasion with a brand-new podcast episode featuring Magnus Ivarsson, CSO of AstronauTx and Prof. Liz C...

Closing the gap on rare diseases in 2026

26 Feb 2026

Contributed by Lukas

Ahead of Rare Disease Day 2026, Optimum is marking the occasion with a brand-new podcast episode featuring Hans Schambye, CEO of BOOST Pharma, Jean-Ma...

Why who funds science matters

11 Feb 2026

Contributed by Lukas

🎙️On this International Day of Women and Girls in Science, we’re shifting the spotlight to the women funding the future of innovation. Thi...

Tackling the threat of AMR

13 Nov 2025

Contributed by Lukas

Antimicrobial Resistance (AMR) is an increasingly wide-scale problem. Not contained by borders, and with the ability to turn minor infections into lif...

The ups and downs of ADCs – where to now?

03 Nov 2025

Contributed by Lukas

Just in time for World ADC San Diego 2025 - a brand new episode of the Optimum Perspectives Podcast is live! Join Francois Bertelli of DISCO Phar...

Q&A with CSO Caroline Benn discussing LoQus23's unique approach to Huntington’s disease

05 Aug 2025

Contributed by Lukas

The latest episode of Optimum Perspectives Podcast has just dropped, featuring LoQus23 Therapeutics’ Chief Scientific Officer and founder Caroline B...

Q&A with Professor Ali Tavassoli of Curve Therapeutics: RSC Interdisciplinary Prize winner 2025

25 Jun 2025

Contributed by Lukas

On the latest episode of the Optimum Perspectives podcast, Optimum Strategic Communications’ Managing Director Eva Haas spoke with Curve Therapeutic...

Stronger together: changing the future of muscle wasting condition

28 Feb 2025

Contributed by Lukas

Listen to our Rare Disease Day Optimum Perspecitives podcast special featuring Tahira Mathur, Patient Advocate and Kate Adcock, Director of Research &...

How bioengineered spider silk-based proteins are changing the world

06 Feb 2025

Contributed by Lukas

Want to know how bioengineered spider silk protein fibres can be applied within the textile, biomedical and automobile industries? In the latest ...

How to have a perfect IPO on NASDAQ

23 Jan 2025

Contributed by Lukas

Want to know how to prepare yourself for the perfect IPO on NASDAQ? Hear from Lynn Lewis, CEO of Gilmartin Group, Optimum’s US partner, on the ...

Ariceum Therapeutics: Pioneering research into next-generation radiopharmaceutical therapy targeting hard-to-treat cancers

27 Nov 2024

Contributed by Lukas

The latest epiosde of Optimum Perspectives Podcast features Germo Gericke, CMO of Ariceum Therapeutics. Listen as he discusses how the company aims to...

Kling Biotherapeutics: Using B cell tech to discover new targets and antibodies in cancer

21 Nov 2024

Contributed by Lukas

Great new insights in the Optimum Perspectives' latest podcast edition featuring Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics, ab...

DISCO Pharmaceuticals looks to unlock new drugs with “surfaceome” technology

05 Nov 2024

Contributed by Lukas

In this podcast to mark Lung Cancer Awareness Month, Optimum’s Richard Staines speaks to Roman Thomas, CEO and founder of Disco Pharmaceuticals, on ...

SpliceBio: Celebrating progress in ophthalmology research on World Sight Day

10 Oct 2024

Contributed by Lukas

Optimum’s Richard Staines talks to Feride Sahin, Senior Director of Clinical Development at Splice Bio about the importance of World Sight Day, whic...

Heidelberg Pharma – turning deadly mushroom toxin into cancer medicine

12 Sep 2024

Contributed by Lukas

It’s time to talk about mushrooms! Or rather the deadly toxin amanitin found in the death cap mushroom, which Heidelberg Pharma is using as a cancer...

Resolution Therapeutics: pioneering macrophage therapies for liver diseases

08 Aug 2024

Contributed by Lukas

Check out Optimum’s latest podcast episode profiling our client Resolution Therapeutics. Lara Campana, VP of Research Operations outlines the compan...

Q&A with Dr Ruth McKernan CBE: Neuroscientist, businesswoman and innovation leader

25 Jul 2024

Contributed by Lukas

Dr Ruth McKernan CBE is the richly deserved winner of the 2024 Mediscience Award for ‘Most Significant Contribution to the Mediscience Sector’. In...

How AI is revolutionising drug research

30 May 2024

Contributed by Lukas

Listen to expert discussion on the role of AI in drug development, featuring Tushar Pandey, CEO and Co-founder of SimBioSys, and Jeremy Skillington, C...

Curve Therapeutics – Addressing challenging drug targets

23 May 2024

Contributed by Lukas

Southampton-based Curve Therapeutics recently raised a hefty £40m in a Series A financing round. In this in-depth podcast, CEO Simon Kerry descr...

Biotech IPOs make a comeback in 2024

16 May 2024

Contributed by Lukas

Listen to the latest insights from Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International, on how...

Anglonordic Life Science Conference strikes optimistic note for ‘24

07 May 2024

Contributed by Lukas

Check out Optimum’s latest Optimum Perspectives Podcast episode featuring the stars of the 20th Anglonordic Life Science Conference in London. ...

The challenges of recruitment for clinical trials

04 Apr 2024

Contributed by Lukas

Diverse recruitment for clinical trials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum’s Ric...

Lytix Biopharma – Innovations in Killing Cancer

07 Mar 2024

Contributed by Lukas

Following recent encouraging interim clinical results, hear Øystein Rekdal, CEO of Lytix Biopharma, discuss with Optimum's Nick Bastin how the compan...

Tackling Rare Diseases in 2024

29 Feb 2024

Contributed by Lukas

To mark Rare Disease Day on 29 February, Optimum Perspectives podcast interviews a panel of experts who discuss the opportunities and challenges for d...

International Day of Women & Girls in Science: Breaking barriers and channeling your inner cavewoman

08 Feb 2024

Contributed by Lukas

In this Optimum Perspectives celebratory episode for International Day of Women & Girls in Science, hear from five influential women on ...

Optimum's European Life Sciences Investor Survey 2024

23 Jan 2024

Contributed by Lukas

Happy 1st birthday to the Optimum Perspectives Podcast! Since launching, 1000s of listens have grown the show into an excellent hub of intel from top ...

Vicore Pharma: Restoring lung function for IPF patients

12 Dec 2023

Contributed by Lukas

Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis (IPF), C21. I...

Optimum's Christmas charity special featuring Ariana Smiles

06 Dec 2023

Contributed by Lukas

In this insightful and emotional podcast episode, the co-founder of Ariana Smiles - a Special Named Fund at CCLG UK, Stephanie Seales Gabbitas shares ...

4SC: Creating a new treatment paradigm for CTCL

21 Nov 2023

Contributed by Lukas

There is a lack of effective treatments for Cutaneous T-Cell Lymphoma (CTCL) – in this podcast episode Jason Loveridge, CEO of 4SC, talked to Optimu...

Episode 10: Optimum's 15th Annual Healthcare Investor Conference Special

02 Nov 2023

Contributed by Lukas

Optimum celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! In the latest ep...

Ask Eva: biopharma's market trends in 2023

07 Sep 2023

Contributed by Lukas

Episode 9 of Optimum Perspectives Podcast features Optimum's Richard Staines and Eva Haas, who discuss the hot areas for investment in the shifting bi...

Alchemab: The UK biotech that is revolutionising drug discovery

22 Aug 2023

Contributed by Lukas

Alchemab aims to revolutionise drug discovery with a novel alternative to the classic “choose a target” approach. Alchemab specifically looks...

Poolbeg Pharma: Using AI to prepare for the next pandemic

08 Aug 2023

Contributed by Lukas

No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma. Optimum Strat...

Verona Pharma: Preparing a potentially novel COPD medicine for market

24 Jul 2023

Contributed by Lukas

A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application to the U....

Søren Møller of Novo Holdings Seed Investments – Helping small biotechs weather the storm

26 Jun 2023

Contributed by Lukas

Today’s funding environment for small biotechs is tough. Valuations are down and money is tighter than it used to be – both for publicly listed an...

Renée Aguiar-Lucander, CEO of Calliditas Therapeutics: Blazing a trail in rare diseases

13 Jun 2023

Contributed by Lukas

How do you take a tiny private Swedish biotech and turn it into a successful, publicly-listed company operating on both sides of the Atlantic, in just...

An interview with Dan Mahony, UK Government Life Sciences Envoy, by Optimum’s Eva Haas

27 Apr 2023

Contributed by Lukas

In this episode, our in-house IR expert, and ex-Fund Manager Eva Haas interviewed Dan Mahony, Chairman of the BioIndustry Association (BIA), following...

Versameb: Revolutionizing SUI therapy with mRNA technology 

19 Apr 2023

Contributed by Lukas

Stress urinary incontinence (SUI) is a common and debilitating problem for many women, particularly after childbirth or in later years. Yet, desp...

CellCentric's new oral cancer therapy inobrodib

23 Jan 2023

Contributed by Lukas

Our host Richard Staines, Account Director at Optimum, discusses the latest clinical findings from inobrodib, an oral cancer therapy developed by the ...